-
1
-
-
49249100260
-
A practical "aBCDE" approach to the metabolic syndrome
-
Blaha MJ, Bansal S, Rouf R, et al. A practical "ABCDE" approach to the metabolic syndrome. Mayo Clin Proc 2008;83:932-43.
-
(2008)
Mayo Clin Proc
, vol.83
, pp. 932-943
-
-
Blaha, M.J.1
Bansal, S.2
Rouf, R.3
-
3
-
-
16844384330
-
Cardiac rehabilitation and exercise training programs in metabolic syndrome and diabetes
-
Lavie CJ, Milani RV. Cardiac rehabilitation and exercise training programs in metabolic syndrome and diabetes. J Cardiopulm Rehabil 2005;25:59-66.
-
(2005)
J Cardiopulm Rehabil
, vol.25
, pp. 59-66
-
-
Lavie, C.J.1
Milani, R.V.2
-
4
-
-
0842277242
-
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition
-
DOI 10.1161/01.CIR.0000111245.75752.C6
-
Brewer SM, Grundy HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8. (Pubitemid 38133916)
-
(2004)
Circulation
, vol.109
, Issue.3
, pp. 433-438
-
-
Grundy, S.M.1
Brewer Jr., H.B.2
Cleeman, J.I.3
Smith Jr., S.C.4
Lenfant, C.5
-
5
-
-
0031851293
-
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation
-
DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
-
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53. (Pubitemid 28319935)
-
(1998)
Diabetic Medicine
, vol.15
, Issue.7
, pp. 539-553
-
-
Alberti, K.G.M.M.1
Zimmet, P.Z.2
-
6
-
-
0035897696
-
Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Executive and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Executive And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
-
(2001)
JAMA
, vol.285
, pp. 2486-2497
-
-
-
7
-
-
70350245011
-
Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention
-
National Heart, Lung, and Blood Institute; American Heart Association;i World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
-
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120: 1640-5.
-
(2009)
Circulation
, vol.120
, pp. 1640-1645
-
-
Alberti, K.G.1
Eckel, R.H.2
Grundy, S.M.3
-
9
-
-
65549109680
-
Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss
-
Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925-32.
-
(2009)
J Am Coll Cardiol
, vol.53
, pp. 1925-1932
-
-
Lavie, C.J.1
Milani, R.V.2
Ventura, H.O.3
-
10
-
-
4644279733
-
Increasing prevalence of the metabolic syndrome among U.S. adults
-
DOI 10.2337/diacare.27.10.2444
-
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004;27: 2444-9. (Pubitemid 39281399)
-
(2004)
Diabetes Care
, vol.27
, Issue.10
, pp. 2444-2449
-
-
Ford, E.S.1
Giles, W.H.2
Mokdad, A.H.3
-
11
-
-
0037861906
-
Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation
-
DOI 10.1016/S0002-9149(03)00464-8
-
Milani RV, Lavie CJ. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am J Cardiol 2003;92: 50-4. (Pubitemid 36782309)
-
(2003)
American Journal of Cardiology
, vol.92
, Issue.1
, pp. 50-54
-
-
Milani, R.V.1
Lavie, C.J.2
-
12
-
-
34247193564
-
Metabolic syndrome: Is it a syndrome? Does it matter?
-
DOI 10.1161/CIRCULATIONAHA.106.658336, PII 0000301720070403000017
-
Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007;115:1806-10. (Pubitemid 46648618)
-
(2007)
Circulation
, vol.115
, Issue.13
, pp. 1806-1810
-
-
Kahn, R.1
-
13
-
-
33746429613
-
Does the metabolic syndrome exist?
-
DOI 10.2337/dc05-2307
-
Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006;29:1689-92. (Pubitemid 44127605)
-
(2006)
Diabetes Care
, vol.29
, Issue.7
, pp. 1689-1692
-
-
Grundy, S.M.1
-
14
-
-
34547327365
-
The individual components of the metabolic syndrome: Is there a raison d'etre?
-
Reaven GM. The individual components of the metabolic syndrome: is there a raison d'etre? J Am Coll Nutr 2007;26:191-5. (Pubitemid 47134700)
-
(2007)
Journal of the American College of Nutrition
, vol.26
, Issue.3
, pp. 191-195
-
-
Reaven, G.M.1
-
15
-
-
33748364584
-
Clinical use of the metabolic syndrome: Why the confusion?
-
Blaha M, Elasy TA. Clinical use of the metabolic syndrome: why the confusion? Clin Diabetes 2006;24:125-31.
-
(2006)
Clin Diabetes
, vol.24
, pp. 125-1231
-
-
Blaha, M.1
Elasy, T.A.2
-
16
-
-
0042665536
-
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study
-
DOI 10.1161/01.CIR.0000080897.52664.94
-
Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9. (Pubitemid 36935533)
-
(2003)
Circulation
, vol.108
, Issue.4
, pp. 414-419
-
-
Sattar, N.1
Gaw, A.2
Scherbakova, O.3
Ford, I.4
O'Reilly, D.St.J.5
Haffner, S.M.6
Isles, C.7
Macfarlane, P.W.8
Packard, C.J.9
Cobbe, S.M.10
Shepherd, J.11
-
17
-
-
0037021505
-
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
-
DOI 10.1001/jama.288.21.2709
-
Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16. (Pubitemid 35403784)
-
(2002)
Journal of the American Medical Association
, vol.288
, Issue.21
, pp. 2709-2716
-
-
Lakka, H.-M.1
Laaksonen, D.E.2
Lakka, T.A.3
Niskanen, L.K.4
Kumpusalo, E.5
Tuomilehto, J.6
Salonen, J.T.7
-
18
-
-
4444222221
-
Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults
-
DOI 10.1161/01.CIR.0000140677.20606.0E
-
Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110: 1245-50. (Pubitemid 39202340)
-
(2004)
Circulation
, vol.110
, Issue.10
, pp. 1245-1250
-
-
Malik, S.1
Wong, N.D.2
Franklin, S.S.3
Kamath, T.V.4
L'Italien, G.J.5
Pio, J.R.6
Williams, G.R.7
-
19
-
-
0037407403
-
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
-
DOI 10.2337/diabetes.52.5.1210
-
Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52: 1210-4. (Pubitemid 36523358)
-
(2003)
Diabetes
, vol.52
, Issue.5
, pp. 1210-1214
-
-
Alexander, C.M.1
Landsman, P.B.2
Teutsch, S.M.3
Haffner, S.M.4
-
20
-
-
79955521241
-
The impact of gemfibrizol, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study
-
Krasuski RA, Devendra GP, Cater G, et al. The impact of gemfibrizol, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. Am J Med Sci 2011;341:xxx-xxx.
-
(2011)
Am J Med Sci
, vol.341
-
-
Krasuski, R.A.1
Devendra, G.P.2
Cater, G.3
-
21
-
-
37449029988
-
Shedding light on high-density lipoprotein cholesterol: The post-ILLUMINATE era
-
Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J Am Coll Cardiol 2008;51: 56-8.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 56-58
-
-
Lavie, C.J.1
Milani, R.V.2
-
22
-
-
59049091800
-
The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: A new era in atherosclerosis management
-
Cardenas GA, Lavie CJ, Cardenas V, et al. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med 2008;9:239-58.
-
(2008)
Rev Cardiovasc Med
, vol.9
, pp. 239-258
-
-
Cardenas, G.A.1
Lavie, C.J.2
Cardenas, V.3
-
23
-
-
33846637379
-
Triglycerides and the risk of coronary heart disease: 10 158 Incident cases among 262 525 participants in 29 Western prospective studies
-
DOI 10.1161/CIRCULATIONAHA.106.637793, PII 0000301720070130000007
-
Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115: 450-8. (Pubitemid 46184196)
-
(2007)
Circulation
, vol.115
, Issue.4
, pp. 450-458
-
-
Sarwar, N.1
Danesh, J.2
Eiriksdottir, G.3
Sigurdsson, G.4
Wareham, N.5
Bingham, S.6
Boekholdt, S.M.7
Khaw, K.-T.8
Gudnason, V.9
-
24
-
-
2542461241
-
Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal
-
DOI 10.1016/j.jacc.2004.03.046, PII S0735109704007168
-
O'Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6. (Pubitemid 38686815)
-
(2004)
Journal of the American College of Cardiology
, vol.43
, Issue.11
, pp. 2142-2146
-
-
O'Keefe Jr., J.H.1
Cordain, L.2
Harris, W.H.3
Moe, R.M.4
Vogel, R.5
-
25
-
-
77951719670
-
Using apolipoprotein B to manage dyslipidemic patients: Time for a change?
-
Harper CR, Jacobson TA. Using apolipoprotein B to manage dyslipidemic patients: time for a change? Mayo Clin Proc 2010;85:440-5.
-
(2010)
Mayo Clin Proc
, vol.85
, pp. 440-445
-
-
Harper, C.R.1
Jacobson, T.A.2
-
26
-
-
77951745342
-
To B or not to B: Is non-highdensity lipoprotein cholesterol an adequate surrogate for apolipoprotein B?
-
Lavie CJ, Milani RV, O'Keefe JH. To B or not to B: is non-highdensity lipoprotein cholesterol an adequate surrogate for apolipoprotein B? Mayo Clin Proc 2010;85:446-50.
-
(2010)
Mayo Clin Proc
, vol.85
, pp. 446-450
-
-
Lavie, C.J.1
Milani, R.V.2
O'Keefe, J.H.3
-
27
-
-
3142729178
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
-
DOI 10.1161/01.CIR.0000133317.49796.0E
-
Grundy SM, Cleeman JL, Mercz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines [published correction appears in Circulation. 2004;110(6): 763]. Circulation 2004;110:227-39. (Pubitemid 38924592)
-
(2004)
Circulation
, vol.110
, Issue.2
, pp. 227-239
-
-
Grundy, S.M.1
Cleeman, J.I.2
Bairey Merz, C.N.3
Brewer Jr., H.B.4
Clark, L.T.5
Hunninghake, D.B.6
Pasternak, R.C.7
Smith Jr., S.C.8
Stone, N.J.9
-
28
-
-
58249086417
-
Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk
-
Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-22.
-
(2009)
J Am Coll Cardiol
, vol.53
, pp. 316-322
-
-
Robinson, J.G.1
Wang, S.2
Smith, B.J.3
-
29
-
-
72549104133
-
Are you targeting non high-density lipoprotein cholesterol [editorial]?
-
Robinson JG. Are you targeting non high-density lipoprotein cholesterol [editorial]? J Am Coll Cardiol 2009;55:42-4.
-
(2009)
J Am Coll Cardiol
, vol.55
, pp. 42-44
-
-
Robinson, J.G.1
-
30
-
-
67849129098
-
Omega-3 polyunsaturated fatty acids and cardiovascular diseases
-
Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54: 585-94.
-
(2009)
J Am Coll Cardiol
, vol.54
, pp. 585-594
-
-
Lavie, C.J.1
Milani, R.V.2
Mehra, M.R.3
-
31
-
-
41549119047
-
Omega-3 fatty acids for cardioprotection
-
DOI 10.4065/83.3.324
-
Lee JH, O'Keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83:324-32. (Pubitemid 351469243)
-
(2008)
Mayo Clinic Proceedings
, vol.83
, Issue.3
, pp. 324-332
-
-
Lee, J.H.1
O'Keefe, J.H.2
Lavie, C.J.3
Marchioli, R.4
Harris, W.S.5
-
32
-
-
78651350459
-
Reduction in the incidence of type 2 diabetes with the Mediterranean Diet: Results of the PREDIMED- Reus Nutrition Intervention Randomized trial
-
Salas-Salvadó J, Bullo M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean Diet: results of the PREDIMED- Reus Nutrition Intervention Randomized trial. Diabetes Care 2011;34:14-9.
-
(2011)
Diabetes Care
, vol.34
, pp. 14-19
-
-
Salas-Salvadó, J.1
Bullo, M.2
Babio, N.3
-
33
-
-
78649427571
-
Effects of aerobic and resistance training on hemoglobin A1c levels in patients with Type 2 diabetes: A randomized controlled trial
-
Church TS, Blair SN, Cocreham S, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with Type 2 diabetes: a randomized controlled trial. JAMA 2010:304:2253-62.
-
(2010)
JAMA
, vol.304
, pp. 2253-2262
-
-
Church, T.S.1
Blair, S.N.2
Cocreham, S.3
-
34
-
-
64749101185
-
Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease
-
Lavie CJ, Thomas RJ, Squires RW, et al. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc 2009;84:373-83.
-
(2009)
Mayo Clin Proc
, vol.84
, pp. 373-383
-
-
Lavie, C.J.1
Thomas, R.J.2
Squires, R.W.3
-
35
-
-
0037034257
-
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
-
DOI 10.1056/NEJMoa012512
-
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.6
, pp. 393-403
-
-
Knowler, W.C.1
Barrett-Connor, E.2
Fowler, S.E.3
Hamman, R.F.4
Lachin, J.M.5
Walker, E.A.6
Nathan, D.M.7
-
36
-
-
0035799806
-
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
-
DOI 10.1056/NEJM200105033441801
-
Tuomilheto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50. (Pubitemid 32378388)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.18
, pp. 1343-1350
-
-
Tuomilehto, J.1
Lindstrom, J.2
Eriksson, J.G.3
Valle, T.T.4
Hamalainen, H.5
Ianne-Parikka, P.6
Keinanen-Kiukaanniemi, S.7
Laakso, M.8
Louheranta, A.9
Rastas, M.10
Salminen, V.11
Uusitupa, M.12
-
37
-
-
79959837992
-
Impact of physical activity, cardiorespiratory fitness, and exercise training on markers of inflammation
-
[published online ahead of print March 21, 2011] doi: 10.1097/HCR.0b013e3182122827
-
Lavie CJ, Church TS, Milani RV, et al. Impact of physical activity, cardiorespiratory fitness, and exercise training on markers of inflammation [published online ahead of print March 21, 2011]. J Cardiopulm Rehabil Prev doi: 10.1097/HCR.0b013e3182122827.
-
J Cardiopulm Rehabil Prev
-
-
Lavie, C.J.1
Church, T.S.2
Milani, R.V.3
-
38
-
-
0032572086
-
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
-
DOI 10.1001/jama.279.20.1615
-
Downs JR, Clearfield M, Weis S, et al. AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA 1998;279:1615-22. (Pubitemid 28248586)
-
(1998)
Journal of the American Medical Association
, vol.279
, Issue.20
, pp. 1615-1622
-
-
Downs, J.R.1
Clearfield, M.2
Weis, S.3
Whitney, E.4
Shapiro, D.R.5
Beere, P.A.6
Langendorfer, A.7
Stein, E.A.8
Kruyer, W.9
Gotto Jr., A.M.10
-
39
-
-
0037420492
-
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
-
DOI 10.1016/S0140-6736(03)12948-0
-
Sever PS, Dahlof B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58. (Pubitemid 36398384)
-
(2003)
Lancet
, vol.361
, Issue.9364
, pp. 1149-1158
-
-
Sever, P.S.1
Dahlof, B.2
Poulter, N.R.3
Wedel, H.4
Beevers, G.5
Caulfield, M.6
Collins, R.7
Kjeldsen, S.E.8
Kristinsson, A.9
McInnes, G.T.10
Mehlsen, J.11
Nieminen, M.12
O'Brien, E.13
Ostergren, J.14
-
40
-
-
72549118057
-
Beyond low-density lipoprotein cholesterol: Respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/highdensity lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women
-
Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/highdensity lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009;55:35-41.
-
(2009)
J Am Coll Cardiol
, vol.55
, pp. 35-41
-
-
Arsenault, B.J.1
Rana, J.S.2
Stroes, E.S.3
-
41
-
-
34248159606
-
Statin wars - Emphasis on potency vs event reduction and safety?
-
Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety? Mayo Clin Proc 2007;82:539-42. (Pubitemid 46709420)
-
(2007)
Mayo Clinic Proceedings
, vol.82
, Issue.5
, pp. 539-542
-
-
Lavie, C.J.1
Milani, R.V.2
O'Keefe, J.H.3
-
42
-
-
77949334766
-
High-dose atorvastatin in acute coronary and cerebrovascular syndromes
-
Lavie CJ, Milani RV. High-dose atorvastatin in acute coronary and cerebrovascular syndromes. J Am Coll Cardiol Intv 2010;3:340-2.
-
(2010)
J Am Coll Cardiol Intv
, vol.3
, pp. 340-342
-
-
Lavie, C.J.1
Milani, R.V.2
-
44
-
-
33748303084
-
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study
-
DOI 10.1016/S0140-6736(06)69292-1, PII S0140673606692921
-
Deedwania P, Barter P, Carmena R, et al. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-28. (Pubitemid 44331360)
-
(2006)
Lancet
, vol.368
, Issue.9539
, pp. 919-928
-
-
Deedwania, P.1
Barter, P.2
Carmena, R.3
Fruchart, J.-C.4
Grundy, S.M.5
Haffner, S.6
Kastelein, J.J.7
LaRosa, J.C.8
Schachner, H.9
Shepherd, J.10
Waters, D.D.11
-
45
-
-
0023726344
-
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
-
Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
-
(1988)
JAMA
, vol.260
, pp. 641-651
-
-
Manninen, V.1
Elo, M.O.2
Frick, M.H.3
-
46
-
-
0033527030
-
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
-
DOI 10.1056/NEJM199908053410604
-
Bloomfield H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8. (Pubitemid 29362514)
-
(1999)
New England Journal of Medicine
, vol.341
, Issue.6
, pp. 410-418
-
-
Rubins, H.B.1
Robins, S.J.2
Collins, D.3
Fye, C.L.4
Anderson, J.W.5
Elam, M.B.6
Faas, F.H.7
Linares, E.8
Schaefer, E.J.9
Schectman, G.10
Wilt, T.J.11
Wittes, J.12
-
47
-
-
28044452217
-
Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
-
Keech A, Simes RJ, Barter P, et al. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-61.
-
(2005)
Lancet
, vol.366
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
-
48
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
for the ACCORD Study Group
-
Ginsberg HN, Elam MB, Lovato LC, et al; for the ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
-
(2010)
N Engl J Med
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
-
49
-
-
0035328230
-
Niacin in patients with diabetes mellitus and coronary artery disease
-
PII S0002914901015417
-
Lavie CJ, Milani RV. Niacin in patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2001;87:1137-8. (Pubitemid 32710341)
-
(2001)
American Journal of Cardiology
, vol.87
, Issue.9
, pp. 1137-1138
-
-
Lavie, C.J.1
Milani, R.V.2
-
50
-
-
0034644442
-
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial
-
for the ADMIT Investigators
-
Elam MB, Hunninghake DB, Davis KB, et al; for the ADMIT Investigators. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 2000;284:1263-70.
-
(2000)
JAMA
, vol.284
, pp. 1263-1270
-
-
Elam, M.B.1
Hunninghake, D.B.2
Davis, K.B.3
-
51
-
-
0037158150
-
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial
-
DOI 10.1001/archinte.162.14.1568
-
Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162:1568-76. (Pubitemid 34765005)
-
(2002)
Archives of Internal Medicine
, vol.162
, Issue.14
, pp. 1568-1576
-
-
Grundy, S.M.1
Vega, G.L.2
McGovern, M.E.3
Tulloch, B.R.4
Kendall, D.M.5
Fitz-Patrick, D.6
Ganda, O.P.7
Rosenson, R.S.8
Buse, J.B.9
Robertson, D.D.10
Sheehan, J.P.11
-
52
-
-
11844304073
-
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)
-
DOI 10.1016/j.amjcard.2004.09.013, PII S0002914904015334
-
Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7. (Pubitemid 40092094)
-
(2005)
American Journal of Cardiology
, vol.95
, Issue.2
, pp. 254-257
-
-
Canner, P.L.1
Furberg, C.D.2
Terrin, M.L.3
McGovern, M.E.4
-
53
-
-
0027077502
-
Marked benefit with sustained-release niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease
-
DOI 10.1016/0002-9149(92)90868-Y
-
Lavie CJ, Mailander L, Milani RV. Marked benefit with sustainedrelease niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69:1083-5. (Pubitemid 23059008)
-
(1992)
American Journal of Cardiology
, vol.69
, Issue.12
, pp. 1083-1085
-
-
Lavie, C.J.1
Mailander, L.2
Milani, R.V.3
-
54
-
-
10044281651
-
Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
-
Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7.
-
(2004)
Circulation
, vol.110
, pp. 3512-3517
-
-
-
55
-
-
72049129430
-
Extended-release niacin or ezetimibe and carotid intima-media thickness
-
Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361: 2113-22.
-
(2009)
N Engl J Med
, vol.361
, pp. 2113-2122
-
-
Taylor, A.J.1
Villines, T.C.2
Stanek, E.J.3
-
56
-
-
0035969564
-
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
-
DOI 10.1056/NEJMoa011090
-
Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. (Pubitemid 33126837)
-
(2001)
New England Journal of Medicine
, vol.345
, Issue.22
, pp. 1583-1592
-
-
Brown, B.G.1
Zhao, X.-Q.2
Chait, A.3
Fisher, L.D.4
Cheung, M.C.5
Morse, J.S.6
Dowdy, A.A.7
Marino, E.K.8
Bolson, E.L.9
Alaupovic, P.10
Frohlich, J.11
Serafini, L.12
Huss-Frechette, E.13
Wang, S.14
DeAngelis, D.15
Dodek, A.16
Albers, J.J.17
-
58
-
-
0023910325
-
Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid
-
Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
-
(1988)
Acta Med Scand
, vol.223
, pp. 405-418
-
-
Carlson, L.A.1
Rosenhamer, G.2
-
59
-
-
0021350001
-
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
-
The Lipid Research Clinics Coronary Primary Prevention Trial T investigators
-
The Lipid Research Clinics Coronary Primary Prevention Trial T investigators. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
-
(1984)
JAMA
, vol.251
, pp. 351-364
-
-
-
60
-
-
33947120281
-
Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes
-
DOI 10.1016/j.clinthera.2007.01.003, PII S0149291807000173
-
Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucoselowering effect of WelChol study (GLOWS): a randomized, doubleblind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83. (Pubitemid 46414026)
-
(2007)
Clinical Therapeutics
, vol.29
, Issue.1
, pp. 74-83
-
-
Zieve, F.J.1
Kalin, M.F.2
Schwartz, S.L.3
Jones, M.R.4
Bailey, W.L.5
-
61
-
-
33645735636
-
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia
-
Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198-205.
-
(2006)
Am J Cardiol
, vol.97
, pp. 1198-1205
-
-
Bays, H.E.1
Davidson, M.2
Jones, M.R.3
-
62
-
-
70450199759
-
Rediscovering bile acid sequestrants
-
Bell DS, O'Keefe JH. Rediscovering bile acid sequestrants. Diabetes Obes Metab 2009;11:1114-21.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 1114-1121
-
-
Bell, D.S.1
O'Keefe, J.H.2
-
63
-
-
79551673658
-
Strategies for optimizing glycemic control and cardiovascular prognosis in type 2 diabetes mellitus
-
O'Keefe JH, Abuannadi M, Lavie CJ, et al. Strategies for optimizing glycemic control and cardiovascular prognosis in type 2 diabetes mellitus. Mayo Clin Proc 2011;86:128-38.
-
(2011)
Mayo Clin Proc
, vol.86
, pp. 128-138
-
-
O'Keefe, J.H.1
Abuannadi, M.2
Lavie, C.J.3
-
64
-
-
64749096151
-
Impact of ezetimibe on atherosclerosis: Is the jury still out?
-
Badarin FJ, Kullo IJ, Kopecky SL, et al. Impact of ezetimibe on atherosclerosis: is the jury still out? Mayo Clin Proc 2009;84:353-61.
-
(2009)
Mayo Clin Proc
, vol.84
, pp. 353-361
-
-
Badarin, F.J.1
Kullo, I.J.2
Kopecky, S.L.3
-
65
-
-
41649107358
-
Simvastatin with or without ezetimibe in familial hypercholesterolemia
-
DOI 10.1056/NEJMoa0800742
-
Kastelein JJ, Akdim F, Stroes ES, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia [published correction appears in N Engl J Med. 2008;358:1977]. N Engl J Med 2008;358:1431-43. (Pubitemid 351482735)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.14
, pp. 1431-1443
-
-
Kastelein, J.J.P.1
Akdim, F.2
Stroes, E.S.G.3
Zwinderman, A.H.4
Bots, M.L.5
Stalenhoef, A.F.H.6
Visseren, F.L.J.7
Sijbrands, E.J.G.8
Trip, M.D.9
Stein, E.A.10
Gaudet, D.11
Duivenvoorden, R.12
Veltri, E.P.13
Marais, A.D.14
De Groot, E.15
-
66
-
-
49249089489
-
Intensive lipid intervention in the post-ENHANCE era
-
O'Keefe JH, Bybee KA, Lavie CJ. Intensive lipid intervention in the post-ENHANCE era. Mayo Clin Proc 2008;83:867-9.
-
(2008)
Mayo Clin Proc
, vol.83
, pp. 867-869
-
-
O'Keefe, J.H.1
Bybee, K.A.2
Lavie, C.J.3
-
67
-
-
67549125150
-
The gravity of JUPITER (justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin)
-
O'Keefe JH, Carter MD, Lavie CJ, et al. The gravity of JUPITER (justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin). Postgrad Med 2009;121:113-8.
-
(2009)
Postgrad Med
, vol.121
, pp. 113-118
-
-
O'Keefe, J.H.1
Carter, M.D.2
Lavie, C.J.3
|